<DOC>
	<DOCNO>NCT02945163</DOCNO>
	<brief_summary>Tenofovir+lamivudine+efavirenz still first line regimen combination antiretroviral therapy develop country . Based previous data , aim evaluate whether reduce dose tenofovir efavirenz could decrease incidence side effect scarify virological efficacy .</brief_summary>
	<brief_title>Dosing Tenofovir Efavirenz Antiretroviral Therapy</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>HIV antibody positive Chinese nationality Na√Øve antiretroviral therapy Willing start antiretroviral therapy Provision write informed consent Pregnant , breastfeeding , lactate Females try get pregnant research period Subjects allergic research drug Subjects take drug know impact absorption , distribution , metabolism excretion research drug Any serious active medical psychiatric illness , opinion Investigator , would interfere treatment , assessment , compliance protocol , subject safety . This would include active clinically significant renal , cardiac , pulmonary , vascular , metabolic ( thyroid disorder , adrenal disease ) illness , malignancy Medical psychiatric condition occupational responsibility may preclude compliance protocol Laboratory blood value : Haemoglobin &lt; 9.0 grams/decilitre ( g/dL ) Neutrophil count &lt; 1500/mm3 Platelet count &lt; 75,000/mm3 Aspartate aminotransferase Alanine transaminase &gt; 3 time Upper Limit Normal ( ULN ) Total bilirubin &gt; 3 time Upper Limit Normal ( ULN ) Subjects estimate creatinine clearance &lt; 90 mL/minute</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>